Pharmacokinetics, Bioequivalence and Safety Evaluation of Two Ticagrelor Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects

References

• SmithJN, NegrelliJM, ManekMB, HawesEM, VieraAJ. Diagnosis and management of acute coronary syndrome: an evidence-based update. J Am Board Fam Med. 2015;28(2):283–93. doi:10.3122/jabfm.2015.02.14018925748771
   PubMed Web of Science ®Google Scholar
• ViraniSS, AlonsoA, BenjaminEJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596.31992061
   PubMed Web of Science ®Google Scholar
• TersalviG, BiascoL, CioffiGM, PedrazziniG. Acute coronary syndrome, antiplatelet therapy, and bleeding: a clinical perspective. J Clin Med. 2020;9(7):2064. doi:10.3390/jcm9072064
   Web of Science ®Google Scholar
• Al-SalamaZT, KeatingGM, KeamSJ. Ticagrelor: a review in long term secondary prevention of cardiovascular events. Drugs. 2017;77(18):2025–2036. doi:10.1007/s40265-017-0844-829150806
   PubMed Web of Science ®Google Scholar
• DobeshPP, FinksSW, TrujilloTC. Dual antiplatelet therapy for long-term secondary prevention of atherosclerotic cardiovascular events. Clin Ther. 2020;42(10):2084–2097. doi:10.1016/j.clinthera.2020.08.00332873416
   PubMed Web of Science ®Google Scholar
• PereiraNL, RihalCS, SoDYF, et al. Clopidogrel pharmacogenetics. Circ Cardiovasc Interv. 2019;12(4):e007811. doi:10.1161/CIRCINTERVENTIONS.119.00781130998396
   PubMed Web of Science ®Google Scholar
• WangY, ChenW, LinY, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled Phase II trial. BMJ. 2019;365:l2211. doi:10.1136/bmj.l221131171523
   PubMed Web of Science ®Google Scholar
• DeeksED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs. 2011;71(7):909–933. doi:10.2165/11206850-000000000-0000021568367
   PubMed Web of Science ®Google Scholar
• KubisaMJ, JezewskiMP, GaseckaA, Siller-MatulaJM, PostulaM. Ticagrelor – toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag. 2018;14:129–140. doi:10.2147/TCRM.S15236929398917
   PubMed Web of Science ®Google Scholar
• WangH, QiJ, LiY, et al. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. Br J Clin Pharmacol. 2018;84(1):88–96. doi:10.1111/bcp.1343628921624
   PubMed Web of Science ®Google Scholar
• RosaGM, BiancoD, ValbusaA, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. Expert Opin Drug Metab Toxicol. 2016;12(12):1491–1502. doi:10.1080/17425255.2016.124452427715344
   PubMed Web of Science ®Google Scholar
• GurbelPA, BlidenKP, ButlerK, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–1199. doi:10.1161/CIRCULATIONAHA.109.91945620194878
   PubMed Web of Science ®Google Scholar
• MahaffeyKW, HeldC, WojdylaDM, et al. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014;63(15):1493–1499. doi:10.1016/j.jacc.2014.01.03824561148
   PubMed Web of Science ®Google Scholar
• WallentinL, BeckerRC, BudajA, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi:10.1056/NEJMoa090432719717846
   PubMed Web of Science ®Google Scholar
• AndellP, JamesSK, CannonCP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the platelet inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc. 2015;4(10):e002490. doi:10.1161/JAHA.115.00249026452988
   PubMed Web of Science ®Google Scholar
• AmsterdamEA, WengerNK, BrindisRG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228.25260718
   PubMed Web of Science ®Google Scholar
• LevineGN, BatesER, BittlJA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10)e123–55.27026020
   PubMed Web of Science ®Google Scholar
• ColletJ-P, ThieleH. The ‘Ten Commandments’ for the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;41(37):3495–3497. doi:10.1093/eurheartj/ehaa62433085966
   PubMed Web of Science ®Google Scholar
• WijeyeratneYD, JoshiR, HeptinstallS. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes. Expert Rev Clin Pharmacol. 2012;5(3):257–69. doi:10.1586/ecp.12.1722697589
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation, National Medical Products Administration(NMPA). Guideline on the investigation of bioequivalence. Available from: http://www.cde.org.cn/zdyz.do?method=largePage&id=353342c97683d4fb. Accessed 34, 2021.
   Google Scholar
• FDA. Center for Drug Evaluation and Research (CDER). Guideline for bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Available from: https://www.fda.gov/media/87219/download. Accessed 34, 2021.
   Google Scholar
• TengR, MitchellP, ButlerK. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. Eur J Clin Pharmacol. 2012;68(8):1175–1182. doi:10.1007/s00228-012-1227-422367426
   PubMed Web of Science ®Google Scholar
• FengW, LiuD, WangY, et al. Effects of food and gender on pharmacokinetics of ticagrelor and its main active metabolite AR-C124910XX in healthy Chinese subjects. Int J Clin Pharmacol Ther. 2018;56(8):372–380. doi:10.5414/CP20322029932414
   PubMed Web of Science ®Google Scholar
• BebawyM, ChettyM. Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome. Curr Drug Metab. 2009;10(4):322–328. doi:10.2174/13892000978849899619519340
   PubMed Web of Science ®Google Scholar
• FDA. The label on ticagrelor. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022433s029lbl.pdf. Accessed 34, 2021.
   Google Scholar
• TengR, CarlsonG, HsiaJ. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53(2):182–189. doi:10.5414/CP20220225500486
   PubMed Web of Science ®Google Scholar
• RamamoorthyA, PacanowskiMA, BullJ, ZhangL. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97(3):263–273. doi:10.1002/cpt.6125669658
   PubMed Web of Science ®Google Scholar
• Westlind-JohnssonA, HermannR, HuennemeyerA, et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther. 2006;79(4):339–349. doi:10.1016/j.clpt.2005.11.01516580902
   PubMed Web of Science ®Google Scholar
• HiasaY, TengR, EmanuelssonH. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014;29(4):324–333. doi:10.1007/s12928-014-0277-124935072
   PubMedGoogle Scholar
• LiH, ButlerK, YangL, YangZ, TengR. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Clin Drug Investig. 2012;32(2):87–97. doi:10.2165/11595930-000000000-00000
   PubMed Web of Science ®Google Scholar
• TengR, ButlerK. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. Int J Clin Pharmacol Ther. 2014;52(6):478–491. doi:10.5414/CP20201724755129
   PubMed Web of Science ®Google Scholar
• TengR, MitchellPD, ButlerK. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. J Clin Pharm Ther. 2012;37(4):464–468. doi:10.1111/j.1365-2710.2011.01307.x21967645
   PubMed Web of Science ®Google Scholar